Asia-pacific Cell Therapy Market Forecast 2022-2030
KEY FINDINGS
The Asia-Pacific cell therapy market is predicted to record a CAGR of 15.16% during the forecast period, 2022-2030. Asia-Pacific offers cost-effective manufacturing & operating units for conducting research. Also, several international corporations are increasing their investments in cell therapy in the region. In addition, many companies are collaborating to develop cell therapy products.
MARKET INSIGHTS
Singapore, Thailand, Singapore, Japan, China, India, Australia & New Zealand, and Rest of Asia-Pacific are analyzed for the Asia-Pacific cell therapy market growth assessment. Japan places a strategic emphasis on regenerative medicine due to its geriatric population and its healthcare solutions. Accordingly, the nation has spent millions of dollars on induced pluripotent stem cell research for treating sick organs. Additionally, the country has established itself as a center for induced pluripotent stem cell ((iPS cell) technology. Besides, funding agencies are offering grants to research communities to accelerate stem cell-based scientific research.
Further, companies are submitting applications to the regulatory authorities for approval to commercialize cell therapy products. For instance, Takeda Pharmaceutical Company Limited applied to the Japanese Ministry of Health, Labour, and Welfare in February 2021 to market and manufacture darvadstrocel (development code: Cx601) for treating complex perianal fistulas in Crohn’s disease (CD) patients.
In India, as per the Ministry of Health and Family Welfare, around 800,000 new cancer cases are diagnosed annually. For cancers like leukemia, CAR T-cell therapy has the potential to minimize the three-year conventional treatment using bone marrow transplant, chemotherapy, oral drugs, etc., in just three weeks. As a result, the increasing need for cell therapies is projected to influence market growth.
COMPETITIVE INSIGHTS
Some of the prominent market players are JCR Pharmaceuticals Co Ltd, Vericel Corporation, Stemedica Cell Technologies Inc, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
- 1. Research Scope & Methodology
- 1.1. Study Objectives
- 1.2. Scope Of Study
- 1.3. Methodology
- 1.4. Assumptions & Limitations
- 2. Executive Summary
- 2.1. Market Size & Estimates
- 2.2. Market Overview
- 3. Market Dynamics
- 3.1. Key Drivers
- 3.1.1. Increasing Cellular Therapy Clinical Trials
- 3.1.2. Growth Of Regenerative Medicine
- 3.1.3. High Prevalence Of Chronic Diseases
- 3.2. Key Restraints
- 3.2.1. Increasing Skills Gap
- 3.2.2. High Costs
- 4. Key Analytics
- 4.1. Impact Of Covid-19 On Cell Therapy Market
- 4.2. Key Market Trends
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Buyers Power
- 4.3.2. Suppliers Power
- 4.3.3. Substitution
- 4.3.4. New Entrants
- 4.3.5. Industry Rivalry
- 4.4. Regulatory Framework
- 4.5. Opportunity Matrix
- 4.6. Vendor Landscape
- 5. Market By Cell Type
- 5.1. Stem Cell
- 5.1.1. Bone Marrow
- 5.1.2. Blood
- 5.1.3. Umbilical Cord-derived Stem Cell
- 5.1.4. Adipose-derived Stem Cell
- 5.1.5. Others
- 5.2. Non-stem Cell
- 6. Market By Therapy Type
- 6.1. Autologous
- 6.2. Allogeneic
- 7. Market By Therapeutic Application
- 7.1. Malignancies
- 7.2. Musculoskeletal Disorders
- 7.3. Autoimmune Disorders
- 7.4. Dermatology
- 7.5. Other Applications
- 8. Market By End-user
- 8.1. Hospitals & Clinics
- 8.2. Academic & Research Institutes
- 9. Geographical Analysis
- 9.1. Asia-pacific
- 9.1.1. Market Size & Estimates
- 9.1.2. Key Drivers
- 9.1.3. Key Challenges
- 9.1.4. Key Players
- 9.1.5. Country Analysis
- 9.1.5.1. China
- 9.1.5.2. Japan
- 9.1.5.3. India
- 9.1.5.4. South Korea
- 9.1.5.5. Thailand
- 9.1.5.6. Singapore
- 9.1.5.7. Australia & New Zealand
- 9.1.5.8. Rest Of Asia-pacific
- 10. Competitive Landscape
- 10.1. Key Strategic Developments
- 10.1.1. Mergers & Acquisitions
- 10.1.2. Product Launches & Developments
- 10.1.3. Partnerships & Agreements
- 10.1.4. Business Expansions
- 10.2. Company Profiles
- 10.2.1. Anterogen Co Ltd
- 10.2.2. Bristol Myers Squibb Company
- 10.2.3. Cells For Cells Sa
- 10.2.4. Gilead Sciences Inc
- 10.2.5. Jcr Pharmaceuticals Co Ltd
- 10.2.6. Kolon Tissuegene Inc
- 10.2.7. Medipost Co Ltd
- 10.2.8. Mesoblast Limited
- 10.2.9. Nuvasive Inc
- 10.2.10. Smith & Nephew Plc
- 10.2.11. Stemedica Cell Technologies Inc
- 10.2.12. Vericel Corporation
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook